Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. Company
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
11.29 USD   +2.82%
01/26FDA advisers back the same COVID vaccine for initial shots, boosters
RE
01/26Novavax needs 6 months to produce annual COVID shots that match new variants
RE
01/25Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Novavax, Inc.
Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Number of employees : 1 541 people.
Sales per Business
20202021Delta
Recombinant Vaccines475.60100%1 146.29100% +141.02%
USD in Million
Sales per region
20202021Delta
United States475.60100%1 146.29100% +141.02%
USD in Million
Managers
Name Title Age Since
John C.s Jacobs President, Chief Executive Officer & Director 55 2023
James Kelly Chief Financial Officer, Treasurer & Executive VP 56 2021
Gregory Glenn President-Research & Development 68 2016
Biegie Lee Chief Information Officer & Senior Vice President - 2020
Gale Smith Vice President-Vaccine Development - 2004
Filip Dubovsky Chief Medical Officer & Executive Vice President - 2020
Raburn Mallory Senior Vice President & Head-Clinical Development - 2021
Seth Toback Senior Vice President-Medical Affairs - 2020
Richard Crowley Chief Operating Officer & Executive Vice President 65 2020
Troy Morgan Chief Compliance Officer & Senior Vice President - 2021
Members of the board
Name Title Age Since
James Young Chairman 69 2011
Michael A. McManus Independent Director 79 1998
Richard H. Douglas, Dr. Independent Director 69 2010
Rachel K. King Independent Director 62 2018
David M. Mott Independent Director 56 2020
Gregg Alton Independent Director 57 2020
Margaret G. McGlynn Independent Director 62 2020
Richard J. Rodgers Independent Director 55 2022
John C.s Jacobs President, Chief Executive Officer & Director 55 2023
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 79,231,647 78,140,997 98.6% 727,695 0.9% 98.6%
Shareholders
NameEquities%
The Vanguard Group, Inc. 7,992,228 9.40%
SSgA Funds Management, Inc. 3,655,428 4.30%
BlackRock Fund Advisors 1,878,454 2.21%
Citigroup Global Markets, Inc. (Investment Management) 1,358,275 1.60%
Voloridge Investment Management LLC 1,333,706 1.57%
Perceptive Advisors LLC 1,043,000 1.23%
Geode Capital Management LLC 1,041,232 1.22%
Renaissance Technologies LLC 880,583 1.04%
Goldman Sachs & Co. LLC (Private Banking) 878,989 1.03%
Credit Suisse International (Investment Management) 868,229 1.02%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Novavax, Inc.
Connections : Novavax, Inc.